Real-world evidence on the CamAPS FX hybrid closed-loop system in people living with type 1 diabetes

We analysed real-world data to evaluate the performance of the CamAPS FX hybrid closed-loop system I people living with type 1 diabetes. Users from 19 countries across different age groups who used the system between 1 January 2024, and 31 December 2024, and who had ≥ 60 days of continuous glucose monitor data with ≥ 30% of closed-loop usage were included in the current analysis (N = 35,714). Time in target glucose range (3.9–10 mmol/l) was median (IQR) 69.6% (61.3–77.2) for all users and varied across the different age groups from 62.5% (53.4–71.2) for young adult users aged 18–22 years old to 76.1% (68.9–82.4) for users aged ≥ 65 years. Median (IQR) time spent in hypoglycaemia (< 3.9 mmol/l) was 2.5% (1.4–3.9) overall, and was < 4% across all age groups. Mean glucose and glucose management indicator overall were 8.7 ± 1.2 mmol/l and 7.1 ± 0.5% (53.6 ± 5.8 mmol/mol), respectively. Median (IQR) time in closed-loop was high at 95.7% (92.9‒97.3). This retrospective observational analysis of real-world data demonstrates the performance of the CamAPS FX hybrid closed-loop system with outcomes comparable to those reported from previous randomised controlled studies.